Ebola peptides and immunogenic compositions containing same
AssigneeThe United States of America as represented by the Secretary of the Army
InventorsMary Katherine Hart, Julie Ann Wilson, Gene Garrard Olinger JR., Michael Adam Bailey
Life of this patent
Estimating the term…
Abstract
Using CTL epitopes to the Ebola GP, NP, VP24, VP30, VP35 and VP40 virion proteins, a method and composition for use in inducing an immune response which is protective against infection with Ebola virus is described.
Claims69
An isolated GP Ebola peptide comprising the sequence specified in SEQ ID NO:29, or a peptide fragment comprising at least 9 consecutive amino acids.
An isolated NP Ebola peptide comprising the sequence specified in SEQ ID NO:24.
An isolated NP Ebola peptide comprising the sequence specified in SEQ ID NO:26, SEQ ID NO:27 or SEQ ID NO:28.
An isolated VP24 Ebola peptide comprising the sequence specified in SEQ ID NO:25, or a peptide fragment comprising at least 9 consecutive amino acids.
An isolated VP24 Ebola peptide comprising the sequence specified in SEQ ID NO:30, or a peptide fragment comprising at least 9 consecutive amino acids.
An isolated VP24 Ebola peptide comprising the sequence specified in SEQ ID NO:31, or a peptide fragment comprising at least 9 consecutive amino acids.
An isolated VP30 Ebola peptide comprising the sequence specified in SEQ ID NO:32, or a peptide fragment comprising at least 9 consecutive amino acids.
An isolated VP30 Ebola peptide comprising the sequence specified in SEQ ID NO:33, or a peptide fragment comprising at least 9 consecutive amino acids.
An isolated VP35 Ebola peptide comprising the sequence specified in SEQ ID NO:34, SEQ ID NO:35 or SEQ ID NO:36.
An isolated VP40 Ebola peptide comprising the sequence specified in SEQ ID NO:37, or a peptide fragment comprising at least 9 consecutive amino acids.
An isolated VP40 Ebola peptide comprising the sequence specified in SEQ ID NO:38, or a peptide fragment comprising at least 6 consecutive amino acids.
An isolated VP40 Ebola peptide comprising the sequence specified in SEQ ID NO:39, or a peptide fragment comprising at least 9 consecutive amino acids.
An isolated VP40 Ebola peptide comprising the sequence specified in SEQ ID NO:40, or a peptide fragment comprising at least 8 consecutive amino acids.
An isolated VP40 Ebola peptide comprising the sequence specified in SEQ ID NO:41, or a peptide fragment comprising at least 8 consecutive amino acids.
A DNA fragment which encodes the NP Ebola peptide of claim3.
A recombinant DNA construct comprising:
- (i) a vector, and
- (ii) at least one of the Ebola virus DNA fragments encoding a peptide selected from the group consisting of SEQ ID NOs:
- 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 and 53.
A pharmaceutical composition comprising SEQ ID NO:24, SEQ ID NO:25, or both.
A pharmaceutical composition comprising a peptide selected from the group consisting of SEQ ID NOs:
- 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 and 53, and mixtures thereof, in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant.
A vaccine against Ebola infection comprising a peptide selected from the group consisting of SEQ ID NOs:
- 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 and 53, and mixtures thereof, in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant.
A vaccine against Ebola infection comprising SEQ ID NO:24, SEQ ID NO:25, or both, in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant.
A vaccine against Ebola infection comprising virus replicon particles expressing at least one of the peptides specified by SEQ ID NOs:24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 and 53, in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant.
A vaccine against Ebola infection comprising virus replicon particles expressing at least one of the peptides specified by SEQ ID NOs:24 and 25, in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant.
A method for inducing in a mammal a cytotoxic T lymphocyte response to an Ebola peptide comprising the step of:
- administering to a mammal an immunogenic composition comprising a peptide selected from the group consisting of SEQ ID NOs:
- 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 and 53, and mixtures thereof, in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant,
- under such conditions that the peptide induces a protective cytotoxic T lymphocyte response.
A method for inducing in a mammal a cytotoxic T lymphocyte response to an Ebola peptide comprising the step of:
- administering to a mammal an immunogenic composition comprising a peptide selected from the group consisting of SEQ ID NOs:24 and 25, and mixtures thereof, in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant,
- under such conditions that the peptide induces a protective cytotoxic T lymphocyte response.
A method for inducing in a mammal a cytotoxic T lymphocyte response to an Ebola peptide comprising the step of:
- administering to a mammal a recombinant DNA construct that expresses a peptide selected from the group consisting of SEQ ID NOs:
- 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 and 53, and mixtures thereof, in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant,
- under such conditions that the peptide induces a protective cytotoxic T lymphocyte response.
A method for inducing in a mammal a cytotoxic T lymphocyte response to an Ebola peptide comprising the step of:
- administering to a mammal a recombinant DNA construct that expresses a peptide selected from the group consisting of SEQ ID NOs:24 and 25, and mixtures thereof, in an effective immunogenic amount in a pharmaceutically acceptable carrier and/or adjuvant,
- under such conditions that the peptide induces a protective cytotoxic T lymphocyte response.
An immunogenic composition comprising Ebola peptides VP30, VP35, and VP40.
Dependencies are inferred from the claim text.